A Study of MVA85A in Healthy Infants - Full Text View

Purpose

This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection. This study planned to enroll 2784 infants (126 to 182 days of age) who received study vaccine or control and were followed for 15 - 36 months. The study was conducted at a single site in South Africa.

Condition	Intervention	Phase
Tuberculosis	Biological: MVA85A/AERAS-485 Biological: Candida Skin Test Antigen	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Tuberculosis

Genetic and Rare Diseases Information Center resources: Tuberculosis

U.S. FDA Resources

Further study details as provided by Aeras:

Primary Outcome Measures:

To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. [ Time Frame: AEs recorded 28 days post-vaccination; SAEs recorded for entire study period. ] [ Designated as safety issue: Yes ]
Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination.

Secondary Outcome Measures:

To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants. [ Time Frame: 15 to 36 months post-vaccination ] [ Designated as safety issue: No ]
The number (percentage) of subjects with a diagnosis of tuberculosis based on clinically-derived tuberculosis (TB) diagnostic criteria were summarized by treatment group for all subjects.
To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. [ Time Frame: 28 days post-vaccination ] [ Designated as safety issue: No ]
Intracellular cytokine staining (ICS) assay immune response was expressed as the percentage of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells producing any one of three cytokines (IFN-γ, TNF-α, or IL-2) or any combination of the three cytokines simultaneously after stimulation with an Ag85A peptide pool on a subset of infants.
To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials. [ Time Frame: 7 days post-vaccination ] [ Designated as safety issue: No ]
An ex vivo IFN-γ ELISPOT assay was used to assess specific T cell responses to an Ag85A peptide pool for a subset of infants.
To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. [ Time Frame: 28 days post-vaccination ] [ Designated as safety issue: No ]
Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants.
To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485. [ Time Frame: 15 to 36 months post-vaccination ] [ Designated as safety issue: No ]
Investigations for determining correlates of immune protection to TB will not be completed as planned because the study did not show TB protection in MVA85A/AERAS-485 recipients.
To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. [ Time Frame: 15 to 36 months post-vaccination ] [ Designated as safety issue: No ]
The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group.


Enrollment:	2797
Study Start Date:	July 2009
Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Investigational Vaccine MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.	Biological: MVA85A/AERAS-485 Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu. Other Name: Manufactured by IDT of Germany.
Placebo Comparator: Control Group Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.	Biological: Candida Skin Test Antigen 1 test, administered once as a placebo control. Other Names: Candin(R) Manufactured by Allermed Laboratories of USA.

Detailed Description:

This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in BCG vaccinated infants without tuberculosis or HIV infection. Infants (126 to 182 days) received intradermal (ID) study vaccine (MVA85A/AERAS-485 or Candida skin test antigen control). All infants were to be followed for at least 15 months after the last infant was enrolled into the study. Given completion of enrollment in 21 months, the total duration of follow-up for each infant was scheduled to be at least 15 months and up to 36 months. Infants were to be followed for the entire duration of the study both for the development of tuberculosis and serious adverse events.

On enrollment to the study, eligible infants were assigned to a study group starting with Study Group 1 and were randomized in a 1:1 ratio within a study group to receive either MVA85A/AERAS-485 or Candida skin test antigen control. Infants were assigned to a safety cohort (Study Group 1), then into 1 of 3 immunological assay evaluation groups (Study Groups 2-4), and finally the remainder of infants were assigned into the correlate of protection cohort (Study Group 5). At least 330 infants were to be randomized in Study Group 1, up to 50-60 infants each in Study Groups 2-4, and the remaining infants were randomized in Study Group 5.

Eligibility


Ages Eligible for Study:	126 Days to 182 Days
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age of 126 through 182 days on the day of randomization (Study Day 0)
Written informed consent obtained from the parents/guardian
Weight: by chart >3rd percentile on Study Day 0 or, if < 3rd percentile, infant has shown a stable growth pattern
BCG vaccination within 7 days of birth
Generally good health confirmed by medical history and physical examination within 35 days prior to Study Day 0
Must have received age-appropriate doses of pneumococcal vaccine as recommended by the South African Department of Health but no injection within 14 day prior to Study Day 0
Ability to complete follow-up period as required by the protocol
Completed simultaneous enrollment in the Aeras Vaccine Development Registry protocol

Exclusion Criteria:

Acute illness on Study Day 0
Fever >=37.5 degrees Celsius on Study Day 0
Evidence of significant active infection on Study Day 0
Received a Expanded Program of Immunization (EPI) within 14 days prior to Study Day 0
Historical or virological evidence of individual or maternal human immunodeficiency virus (HIV-1) infection
History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine
Previous medical history, or evidence, of an intercurrent illness that may compromise the safety of the infant in the study
Evidence of chronic hepatitis from any cause
History or evidence of any systemic disease on physical examination or any acute, chronic or intercurrent illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine
History of or known tuberculosis or treatment for tuberculosis
Shared residence since birth with an individual with active tuberculosis or on anti-tuberculosis treatment for less than 2 months

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00953927

Locations


South Africa
South African Tuberculosis Vaccine Initiative (Satellite)
Ceres, South Africa, 6835
South African Tuberculosis Vaccine Initiative (Satellite)
Robertson, South Africa, 6705
South African Tuberculosis Vaccine Initiative (Headquarters)
Worcester, South Africa, 6850

Sponsors and Collaborators

Aeras

University of Oxford

University of Cape Town

Investigators


Principal Investigator:	Michele Tameris, MD	South African Tuberculosis Vaccine Initiative
Study Director:	Bernard Landry, MPH	Aeras
Study Chair:	Helen McShane, MD	University of Oxford; Centre for Vaccinology & Tropical Medicine

More Information

No publications provided by Aeras

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA. Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314.

Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8.


Responsible Party:	Aeras
ClinicalTrials.gov Identifier:	NCT00953927 History of Changes
Other Study ID Numbers:	C-020-485, Oxford TB020
Study First Received:	July 31, 2009
Results First Received:	October 23, 2013
Last Updated:	February 4, 2014
Health Authority:	South Africa: Medicines Control Council South Africa: Human Research Ethics Committee United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:


Tuberculosis Actinomycetales Infections Bacterial Infections Gram-Positive Bacterial Infections Mycobacterium Infections

ClinicalTrials.gov processed this record on March 03, 2015